Select Medical Board Fiduciary Duty Investigation
Analysis based on 40 articles · First reported May 29, 2026 · Last updated Jun 05, 2026
The investigation by Bleichmar Fonti & Auld LLP into Select Medical's board of directors could lead to legal action, potentially impacting the final acquisition price or terms for Select Medical shareholders. This uncertainty may cause fluctuations in Select Medical's stock price until the shareholder vote on June 26, 2026, and the subsequent resolution of the investigation.
Bleichmar Fonti & Auld LLP has announced an investigation into Select Medical's board of directors and senior management. This investigation stems from the pending sale of Select Medical for $16.50 per share to a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe. The law firm is examining potential breaches of fiduciary duties by the board, particularly concerning the $16.50 per share acquisition price and the fact that Ortenzio and Jackson are allowed to 'rollover' their holdings into the post-merger company, an option not extended to public stockholders. The merger, approved by a special committee, is awaiting stockholder approval on June 26, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard